Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 15, 2020

SELL
$3.5 - $13.77 $115,132 - $452,964
-32,895 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$6.21 - $14.02 $204,277 - $461,187
32,895 New
32,895 $450,000

Others Institutions Holding ARAV

About Aravive, Inc.


  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.